Replies to post #62132 on NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

I find it interesting IMUC selected OS again [Time frame 46 months] as their primary endpoint for their current phase III trial.

In two months, approximately, the surviving info arm (DcVax-L) patients should be at 46 months.

Whereas one of NWBO's other endpoints appears to be....

ENDPOINT: Survival at 6, 12, 18, 24, 36 and 48 months.

The latter group in the main trial would have to have started treatment by May 18, 2012.

That German Label enrollment data was from sometime August 2012.